Clinical trials: Acute Non-Lymphocytic Leukemia
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
- Trial name
- NCT06144606
- Testing
- Tecartus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia
DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899652
- Testing
- Southern blotting, chromosomal translocation analysis, cytogenetic analysis
- Volunteers
- 149 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.
- Trial name
- NCT00528333
- Testing
- Lintuzumab (SGN-33), Low dose cytarabine
- Where
- 20 sites in United States
- Volunteers
- 211 people
- Sponsor
- Seagen Inc.
B-Cell Acute Lymphoblastic Leukemia, Adult
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of allogeneic CD19-targeted CAR-γδT Cell in treating CD19-positive relapsed/refractory B-ALL
- Trial name
- NCT06696833
- Testing
- QH10304-BAL-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Myeloid, Acute
Risk-adapted Therapy for Primary Acute Myeloid Leukemia
The AML-12 study investigates the efficacy and toxicity of standard induction chemotherapy with idarubicin and cytarabine (IC) with G-CSF priming followed by a risk-adapted post remission therapy for patients up to the age of 70…
- Trial name
- NCT04687098
- Testing
- Idarubicin, Ara-C, G-CSF
- Where
- 15 sites in Spain
- Volunteers
- 1,034 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
This pilot phase II trial studies whether biomarkers (biological molecules) in bone marrow samples can predict treatment response to sirolimus and chemotherapy (mitoxantrone hydrochloride, etoposide, and cytarabine [MEC]) in…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Trial name
- NCT02583893
- Testing
- Sirolimus, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Lymphoblastic Leukemia, B-cell Lymphoma
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
This study aims to evaluate the safety and feasibility of hCD19.IL15.CAR-iNKT cells in treating patients with relapsed/refractory/high-risk B-cell tumors.
- Conditions
- Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT04814004
- Testing
- hCD19.IL15.CAR-iNKT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Kai Lin Xu; Jun Nian Zheng
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
This phase I trial is to find out the best dose, possible benefits and/or side effects of 90Y-DOTA-anti-CD25 basiliximab given together with fludarabine, melphalan, and total marrow and lymphoid irradiation (TMLI) in treating…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
- Trial name
- NCT05139004
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
This phase II trial is studying how well fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell transplant work in treating patients with acute lymphoblastic leukemia or chronic myelogenous…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase, Childhood Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00036738
- Testing
- Cyclosporine, Dasatinib, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations
The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome.
- Trial name
- AML18 (NCT02272478)
- Testing
- Arm A Mylotarg plus DA Versus CPX-351, Arm B Vosaroxin and Decitabine, Arm D Small molecule or Not
- Where
- 87 sites in Denmark, United Kingdom
- Volunteers
- 1,600 people
- Sponsor
- Cardiff University
Acute Myeloid Leukemia
Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.
- Trial name
- NCT00783653
- Testing
- Sunitinib
- Where
- 5 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid…
- Trial name
- NCT05241093
- Testing
- HYML-122; cytarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tarapeutics Science Inc.
Leukemia
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give…
- Trial name
- NCT00002549
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- 75 sites in Austria, Belgium and 9 more
- Volunteers
- 1,520 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
The purpose of this study is to evaluate how effective lower doses of CPX-351 are in older participants with relapsed/refractory acute myeloid leukemia (AML) who are not eligible to receive intensive chemotherapy and in…
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04668885
- Testing
- CPX-351
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
This phase 2 clinical trial investigates the effectiveness of cytokine-induced memory-like natural killer (CIML NK) cells in combination with FLAG chemotherapy as a treatment for refractory or relapsed AML.
- Trial name
- NCT04354025
- Testing
- Cytokine induced memory-like NK cells, Fludarabine, Ara-C
- Sponsor
- Washington University School of Medicine
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
Phase I trial to study the effectiveness of combining oblimersen with cytarabine and daunorubicin in treating older patients who have previously untreated acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Trial name
- NCT00039117
- Testing
- oblimersen sodium, cytarabine, daunorubicin hydrochloride
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)
The objective of the phase I part of the trial is the determination of the maximum tolerated dose (MTD) of TCP (Tranylcypromine) in combination with fixed-dose ATRA (all-trans-retinoic acid) and with fixed-dose AraC (Cytarabine)…
- Trial name
- TRANSATRA (NCT02717884)
- Testing
- tranylcypromine, all-trans retinoic acid, cytarabine
- Where
- 6 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Michael Luebbert
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
The investigators hypothesize that CX-01 will disrupt the bone marrow microenvironment and increase the cytotoxic effects of azacitidine on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) hematopoietic stem cells…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, AML, MDS
- Trial name
- NCT02995655
- Testing
- CX-01, Azacitidine, Bone marrow biopsy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.
- Trial name
- AML_MenALLO (NCT07627568)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Freiburg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.